Results 121 to 130 of about 8,187 (238)

In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis

open access: yesJournal of Global Antimicrobial Resistance
: Objectives: Gram-negative pathogens causing respiratory infection in people with cystic fibrosis and bronchiectasis are becoming progressively more resistant to conventional antibiotics. Although cefiderocol is licenced for the treatment of infections
Michael M Tunney   +3 more
doaj   +1 more source

Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant Acinetobacter spp. [PDF]

open access: yes
Cefiderocol, a siderophore-cephalosporine conjugate antibiotic, shows promise as a therapeutic option for carbapenem-resistant (CR) Acinetobacter infections. While resistance has already been reported in A. baumannii, combination therapies with avibactam
German Matias Traglia   +20 more
core   +1 more source

Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa

open access: yesJournal of Antimicrobial Chemotherapy
Objectives We aimed to compare the stability of the newly developed β-lactams (cefiderocol) and β-lactam/β-lactamase inhibitor combinations (ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam/avibactam, cefepime/taniborbactam, cefepime/zidebactam ...
Lucía González-Pinto   +15 more
semanticscholar   +1 more source

Cefiderocol. Summary and conclusions

open access: yesRevista Española de Quimioterapia, 2022
Mensa, José, Barberán, José
openaire   +2 more sources

Emergence of cefiderocol resistance during therapy in NDM-5–producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations

open access: yesInternational Journal of Infectious Diseases
Cefiderocol, a siderophore-conjugated cephalosporine, is a promising drug used to treat infection with carbapenem-resistant gram-negative bacteria. Here, we report a case of pneumonia induced by multiple gram-negative pathogens, including a carbapenem ...
Luc Deroche   +8 more
doaj   +1 more source

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

open access: yesAntimicrobial Agents and Chemotherapy
The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S ...
Alina Iovleva   +14 more
semanticscholar   +1 more source

Combinatorial effects of a novel SHV-248 variant, NDM-5, and ompK35 deficiency drive high-level cefiderocol resistance in Klebsiella pneumoniae

open access: yesMicrobiology Spectrum
Cefiderocol holds significant therapeutic value against metallo-β-lactamase-producing Enterobacterales. However, reduced susceptibility to cefiderocol in NDM-producing strains is increasingly observed.
Chuwen Zhao   +7 more
doaj   +1 more source

Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases

open access: yesAntimicrobial Agents and Chemotherapy
The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified in Escherichia coli was evaluated with respect to susceptibility to β-lactam/β-lactamase inhibitor combinations including ceftazidime-avibactam, imipenem-relebactam ...
C. le Terrier   +3 more
semanticscholar   +1 more source

In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations

open access: yesMicrobiology spectrum
Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. represent major threats and have few approved therapeutic options. Non-fermenting Gram-negative isolates were collected from hospitalized inpatients from 49 sites in 6 European countries ...
A. Santerre Henriksen   +56 more
semanticscholar   +1 more source

Challenges Facing Two Outbreaks of Carbapenem-Resistant Acinetobacter baumannii: From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants

open access: yes
Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are associated with poor outcomes depending on patient’s conditions, clinical severity and type of infection, and treatment is challenging given the limited therapeutic options ...
Mª José Asensio-Martín   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy